FDA approves first DNA-based immunotherapy for recurrent airway papillomas

Overview

Updated 55 minutes ago

Adults with recurrent respiratory papillomatosis (RRP) have had one treatment: surgery to shave HPV-grown warts off the vocal cords and airway, often several times a year. On October 30, 2026, the Food and Drug Administration granted accelerated approval to Voceryq, an injected DNA-based immunotherapy meant to reduce how often those operations are needed.

In a 32-patient trial, 7 of the 26 evaluable adults needed no surgery in the 12 months after treatment. That 27% response rate is the basis for approval, and it obliges Inovio to run a confirmatory study through 2032.

Why it matters

RRP patients face repeated airway surgeries; Voceryq is the first approved therapy aimed at the HPV causing them, not just the growths.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

27%

Complete response rate

Share of evaluable patients needing no surgical excision in the 12 months after treatment.

Patients with no surgery at one year

Out of 26 patients who had at least three surgeries in the prior year.

Evaluable patients

The efficacy population from the 32 adults enrolled in study RRP-001.

4.5

Median prior surgeries

Surgical excisions in the 12 months before treatment for the efficacy population.

Minimum confirmatory enrollment

Adults and children the FDA requires in the postmarketing study.

3 years

Required follow-up

How long the confirmatory study must track surgical interventions after treatment.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Jacqueline Shea

President and Chief Executive Officer, INOVIO

Leading INOVIO as its first approved product reaches the market

Organizations Involved

INOVIO Pharmaceuticals

Biotechnology company

Developer and license holder for Voceryq

A Pennsylvania biotech whose DNA medicines are delivered with its proprietary electroporation device.

U.S. Food and Drug Administration

Federal regulator

Granted accelerated approval and set postmarketing requirements

The federal agency that reviewed the biologics license application for Voceryq.

FDA Center for Biologics Evaluation and Research

Federal regulatory agency division

Reviewed the Voceryq biologics license application

The FDA center responsible for regulating biologic products such as vaccines and gene therapies.

Timeline

October 2026 August 2032

7 events Latest: 2 days ago

Tap a bar to jump to that date

August 2032
Final study report due to FDA
Upcoming Scheduled

The report is the basis for deciding whether the approval is confirmed.
August 30th, 2032
December 2031
Confirmatory study completion target
Upcoming Scheduled

The study must track surgical interventions for at least three years.
December 30th, 2031
June 2027
Final confirmatory protocol due
Upcoming Scheduled

The FDA expects to align on the final study design by this date.
June 30th, 2027
December 2026
Draft confirmatory protocol due to FDA
Upcoming Scheduled

INOVIO must submit its proposed design for the postmarketing study.
December 30th, 2026
October 2026
FDA grants accelerated approval to Voceryq
Latest Regulatory

The approval covers adults with RRP and is based on reduced frequency of surgical papilloma excisions.
2 days ago
FDA sets confirmatory trial deadlines
Regulatory

Draft protocol due December 30, 2026; final report due August 30, 2032.
2 days ago
Inovio shares more than triple after hours
Market

The stock reached $2.17 after the approval was announced.
2 days ago

Scenarios

Confirmatory data hold up and FDA converts Voceryq to full approval

Possible Resolves by End of 2032

Discussed by: FDA approval letter; INOVIO

If the postmarketing study reproduces the reduction in surgeries across at least 50 adults and children over three years, the FDA can drop the accelerated-approval conditions. Conversion would stabilize reimbursement and remove the withdrawal risk that hangs over the label.

Confirmatory trial misses its endpoint and FDA moves to withdraw approval

Possible Resolves by Q2 2033

Discussed by: FDA approval letter, which states approval may be withdrawn if the study fails or lacks due diligence

The approval rests on 7 complete responses in 26 patients, a small single-arm result. If the larger study shows no durable reduction in surgery, the FDA has explicit authority to withdraw the indication, as it has for other accelerated approvals.

Pediatric patients gain access through a label expansion

Possible Resolves by End of 2032

Discussed by: FDA approval letter, which requires the confirmatory study to enroll pediatric patients

RRP also affects children, and the required study must include them. If the data support it, INOVIO could seek to extend the indication beyond adults, widening the market and the patient pool.

INOVIO sells or partners the Voceryq franchise before the confirmatory readout

Possible Resolves by End of 2028

Discussed by: Biotech analysts covering INOVIO

Commercializing a first product requires manufacturing, a delivery device, and payer negotiations. A company with no prior launch experience may choose to license rights or sell the asset rather than fund the launch and the confirmatory trial alone.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 2011

FDA withdraws Avastin's breast cancer indication (2011)

Avastin won accelerated approval for metastatic breast cancer in 2008. Follow-up trials showed no improvement in overall survival, and the FDA moved to withdraw the indication over the manufacturer's objection.

Then

Genentech appealed; the FDA commissioner upheld the withdrawal after a hearing.

Now

The drug stayed on the market for other cancers, and the case became the standard example of how accelerated approval can be reversed.

Why this matters now

Voceryq's approval carries the same conditional structure. If the confirmatory study fails, the FDA can pull the indication.

April 2010

Provenge, the first therapeutic cancer vaccine (2010)

The FDA approved sipuleucel-T, a personalized cellular immunotherapy for prostate cancer, as the first therapeutic cancer vaccine. Manufacturing required collecting and processing each patient's own cells.

Then

Launch costs and complex logistics limited uptake despite the approval.

Now

Dendreon filed for bankruptcy in 2014, and the product was later sold.

Why this matters now

A first-in-class immunotherapy can still struggle on delivery and cost. Voceryq needs a proprietary electroporation device and a supply chain INOVIO has never run at commercial scale.

June 2006